Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 261 entries
Sorted by: Best Match Show Resources per page
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.

ACS medicinal chemistry letters

Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, Asano Y, Nakamura A, Nambu T, Hata A, Ishii T, Sameshima T, Debori Y, Miyamoto M, Klein MG, Tjhen R, Sang BC, Levin I, Lane SW, Snell GP, Li K, Kefala G, Hoffman ID, Ding SC, Cary DR, Mizojiri R.
PMID: 31620240
ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. doi: 10.1021/acsmedchemlett.9b00400. eCollection 2019 Oct 10.

General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibitors as...

Cite
Fujimoto J, Kurasawa O, Takagi T, et al. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. ACS Med Chem Lett. 2019;10(10):1498-1503doi: 10.1021/acsmedchemlett.9b00400.
Fujimoto, J., Kurasawa, O., Takagi, T., Liu, X., Banno, H., Kojima, T., Asano, Y., Nakamura, A., Nambu, T., Hata, A., Ishii, T., Sameshima, T., Debori, Y., Miyamoto, M., Klein, M. G., Tjhen, R., Sang, B. C., Levin, I., Lane, S. W., Snell, G. P., Li, K., Kefala, G., Hoffman, I. D., Ding, S. C., Cary, D. R., & Mizojiri, R. (2019). Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. ACS medicinal chemistry letters, 10(10), 1498-1503. https://doi.org/10.1021/acsmedchemlett.9b00400
Fujimoto, Jun, et al. "Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode." ACS medicinal chemistry letters vol. 10,10 (2019): 1498-1503. doi: https://doi.org/10.1021/acsmedchemlett.9b00400
Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, Asano Y, Nakamura A, Nambu T, Hata A, Ishii T, Sameshima T, Debori Y, Miyamoto M, Klein MG, Tjhen R, Sang BC, Levin I, Lane SW, Snell GP, Li K, Kefala G, Hoffman ID, Ding SC, Cary DR, Mizojiri R. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. doi: 10.1021/acsmedchemlett.9b00400. eCollection 2019 Oct 10. PMID: 31620240; PMCID: PMC6792287.
Copy Download .nbib Format: NLM
Characterization of Seminiferous Epithelium Stages in the Wild Javan Muntjac (.

Veterinary medicine international

Wahyuni S, Gholib G, Adnyane IKM, Agil M, Hamny H, Agungpriyono S, Yusuf TL.
PMID: 30026905
Vet Med Int. 2018 Jun 20;2018:3024532. doi: 10.1155/2018/3024532. eCollection 2018.

Stages of the seminiferous epithelium of the testis of the wild Javan muntjac (

Cite
Wahyuni S, Gholib G, Adnyane IKM, et al. Characterization of Seminiferous Epithelium Stages in the Wild Javan Muntjac (. Vet Med Int. 2018;2018:3024532doi: 10.1155/2018/3024532.
Wahyuni, S., Gholib, G., Adnyane, I. K. M., Agil, M., Hamny, H., Agungpriyono, S., & Yusuf, T. L. (2018). Characterization of Seminiferous Epithelium Stages in the Wild Javan Muntjac (. Veterinary medicine international, 20183024532. https://doi.org/10.1155/2018/3024532
Wahyuni, Sri, et al. "Characterization of Seminiferous Epithelium Stages in the Wild Javan Muntjac (." Veterinary medicine international vol. 2018 (2018): 3024532. doi: https://doi.org/10.1155/2018/3024532
Wahyuni S, Gholib G, Adnyane IKM, Agil M, Hamny H, Agungpriyono S, Yusuf TL. Characterization of Seminiferous Epithelium Stages in the Wild Javan Muntjac (. Vet Med Int. 2018 Jun 20;2018:3024532. doi: 10.1155/2018/3024532. eCollection 2018. PMID: 30026905; PMCID: PMC6031200.
Copy Download .nbib Format: NLM
Identification of potentially painful disc fissures in magnetic resonance images using machine-learning modelling.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

Kerstin L, Hanna H, Helerna B.
PMID: 34854974
Eur Spine J. 2021 Dec 02; doi: 10.1007/s00586-021-07066-x. Epub 2021 Dec 02.

PURPOSE: It is suggested that non-specific low back pain (LBP) can be related to nerve ingrowth along granulation tissue in disc fissures, extending into the outer layers of the annulus fibrosus. Present study aimed to investigate if machine-learning modelling...

Cite
Kerstin L, Hanna H, Helerna B. Identification of potentially painful disc fissures in magnetic resonance images using machine-learning modelling. Eur Spine J. 2021;doi: 10.1007/s00586-021-07066-x.
Kerstin, L., Hanna, H., & Helerna, B. (2021). Identification of potentially painful disc fissures in magnetic resonance images using machine-learning modelling. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, . https://doi.org/10.1007/s00586-021-07066-x
Kerstin, Lagerstrand, et al. "Identification of potentially painful disc fissures in magnetic resonance images using machine-learning modelling." European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society vol. (2021). doi: https://doi.org/10.1007/s00586-021-07066-x
Kerstin L, Hanna H, Helerna B. Identification of potentially painful disc fissures in magnetic resonance images using machine-learning modelling. Eur Spine J. 2021 Dec 02; doi: 10.1007/s00586-021-07066-x. Epub 2021 Dec 02. PMID: 34854974.
Copy Download .nbib Format: NLM
Oncotype DX and Prosigna in breast cancer patients: A comparison study.

Cancer treatment and research communications

Abdelhakam DA, Hanna H, Nassar A.
PMID: 33444922
Cancer Treat Res Commun. 2021;26:100306. doi: 10.1016/j.ctarc.2021.100306. Epub 2021 Jan 07.

BACKGROUND: Oncotype Dx® (ODX) is the most used prognostic and predictive assay for ER + breast cancer (BCa) and is categorized into low (< 18), intermediate (18 to 30), or high (≥31) risk of recurrence. Prosigna® is a prognostic...

Cite
Abdelhakam DA, Hanna H, Nassar A. Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer Treat Res Commun. 2021;26:100306doi: 10.1016/j.ctarc.2021.100306.
Abdelhakam, D. A., Hanna, H., & Nassar, A. (2021). Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer treatment and research communications, 26100306. https://doi.org/10.1016/j.ctarc.2021.100306
Abdelhakam, Dina A, et al. "Oncotype DX and Prosigna in breast cancer patients: A comparison study." Cancer treatment and research communications vol. 26 (2021): 100306. doi: https://doi.org/10.1016/j.ctarc.2021.100306
Abdelhakam DA, Hanna H, Nassar A. Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer Treat Res Commun. 2021;26:100306. doi: 10.1016/j.ctarc.2021.100306. Epub 2021 Jan 07. PMID: 33444922.
Copy Download .nbib Format: NLM
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets.

Thrombosis research

Pitkänen HH, Jouppila A, Helin T, Dulipati V, Kotimaa J, Meri S, Kantele A, Jalkanen P, Julkunen I, Lassila R.
PMID: 34768097
Thromb Res. 2021 Dec;208:129-137. doi: 10.1016/j.thromres.2021.10.027. Epub 2021 Nov 06.

BACKGROUND: Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare coagulation disorder reported after administration of COVID-19 adenovirus-vectored vaccines. VITT is mediated by anti-platelet factor 4 (PF4) antibodies activating platelets through the Fcγ-receptor II (FcγRII), and it is associated with strong...

Cite
Pitkänen HH, Jouppila A, Helin T, et al. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thromb Res. 2021;208:129-137doi: 10.1016/j.thromres.2021.10.027.
Pitkänen, H. H., Jouppila, A., Helin, T., Dulipati, V., Kotimaa, J., Meri, S., Kantele, A., Jalkanen, P., Julkunen, I., & Lassila, R. (2021). COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thrombosis research, 208129-137. https://doi.org/10.1016/j.thromres.2021.10.027
Pitkänen, Hanna H, et al. "COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets." Thrombosis research vol. 208 (2021): 129-137. doi: https://doi.org/10.1016/j.thromres.2021.10.027
Pitkänen HH, Jouppila A, Helin T, Dulipati V, Kotimaa J, Meri S, Kantele A, Jalkanen P, Julkunen I, Lassila R. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thromb Res. 2021 Dec;208:129-137. doi: 10.1016/j.thromres.2021.10.027. Epub 2021 Nov 06. PMID: 34768097; PMCID: PMC8571998.
Copy Download .nbib Format: NLM
New Morphological Factor for Predicting Late Proximal Type I Endoleak after Endovascular Aneurysm Repair.

Annals of vascular surgery

Banno H, Sugimoto M, Sato T, Ikeda S, Kawai Y, Tsuruoka T, Kodama A, Komori K.
PMID: 34780964
Ann Vasc Surg. 2021 Nov 12; doi: 10.1016/j.avsg.2021.09.049. Epub 2021 Nov 12.

BACKGROUND: Although we have witnessed several cases of late proximal type I endoleak (T1AEL) after endovascular aneurysm repair (EVAR), most patients did not have "hostile neck" preoperatively. We hypothesized that the distance between the lowest renal artery and the...

Cite
Banno H, Sugimoto M, Sato T, et al. New Morphological Factor for Predicting Late Proximal Type I Endoleak after Endovascular Aneurysm Repair. Ann Vasc Surg. 2021;doi: 10.1016/j.avsg.2021.09.049.
Banno, H., Sugimoto, M., Sato, T., Ikeda, S., Kawai, Y., Tsuruoka, T., Kodama, A., & Komori, K. (2021). New Morphological Factor for Predicting Late Proximal Type I Endoleak after Endovascular Aneurysm Repair. Annals of vascular surgery, . https://doi.org/10.1016/j.avsg.2021.09.049
Banno, Hiroshi, et al. "New Morphological Factor for Predicting Late Proximal Type I Endoleak after Endovascular Aneurysm Repair." Annals of vascular surgery vol. (2021). doi: https://doi.org/10.1016/j.avsg.2021.09.049
Banno H, Sugimoto M, Sato T, Ikeda S, Kawai Y, Tsuruoka T, Kodama A, Komori K. New Morphological Factor for Predicting Late Proximal Type I Endoleak after Endovascular Aneurysm Repair. Ann Vasc Surg. 2021 Nov 12; doi: 10.1016/j.avsg.2021.09.049. Epub 2021 Nov 12. PMID: 34780964.
Copy Download .nbib Format: NLM
The Co-existence of ADHD With Autism in Saudi Children: An Analysis Using Next-Generation DNA Sequencing.

Frontiers in genetics

Bogari NM, Al-Allaf FA, Aljohani A, Taher MM, Qutub NA, Alhelfawi S, Alobaidi A, Alqudah DM, Banni H, Dairi G, Amin AA.
PMID: 33384710
Front Genet. 2020 Dec 15;11:548559. doi: 10.3389/fgene.2020.548559. eCollection 2020.

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Several studies have confirmed the co-existence of other neuropsychiatric disorders with ADHD. Out of 106 individuals suspected to have ADHD, eight Saudi Arabian pediatric patients were diagnosed with...

Cite
Bogari NM, Al-Allaf FA, Aljohani A, et al. The Co-existence of ADHD With Autism in Saudi Children: An Analysis Using Next-Generation DNA Sequencing. Front Genet. 2020;11:548559doi: 10.3389/fgene.2020.548559.
Bogari, N. M., Al-Allaf, F. A., Aljohani, A., Taher, M. M., Qutub, N. A., Alhelfawi, S., Alobaidi, A., Alqudah, D. M., Banni, H., Dairi, G., & Amin, A. A. (2020). The Co-existence of ADHD With Autism in Saudi Children: An Analysis Using Next-Generation DNA Sequencing. Frontiers in genetics, 11548559. https://doi.org/10.3389/fgene.2020.548559
Bogari, Neda M, et al. "The Co-existence of ADHD With Autism in Saudi Children: An Analysis Using Next-Generation DNA Sequencing." Frontiers in genetics vol. 11 (2020): 548559. doi: https://doi.org/10.3389/fgene.2020.548559
Bogari NM, Al-Allaf FA, Aljohani A, Taher MM, Qutub NA, Alhelfawi S, Alobaidi A, Alqudah DM, Banni H, Dairi G, Amin AA. The Co-existence of ADHD With Autism in Saudi Children: An Analysis Using Next-Generation DNA Sequencing. Front Genet. 2020 Dec 15;11:548559. doi: 10.3389/fgene.2020.548559. eCollection 2020. PMID: 33384710; PMCID: PMC7770135.
Copy Download .nbib Format: NLM
Emotion mindsets and depressive symptoms in adolescence: The role of emotion regulation competence.

Emotion (Washington, D.C.)

Skymba HV, Troop-Gordon W, Modi HH, Davis MM, Weldon AL, Xia Y, Heller W, Rudolph KD.
PMID: 33370145
Emotion. 2020 Dec 28; doi: 10.1037/emo0000902. Epub 2020 Dec 28.

Recent theories posit that emotion mindsets (i.e., the extent to which individuals believe emotions are malleable or fixed) play a crucial role in experiences of emotion and influence emotion regulation (ER) processes. Drawing from mindset theory, this study examined...

Cite
Skymba HV, Troop-Gordon W, Modi HH, et al. Emotion mindsets and depressive symptoms in adolescence: The role of emotion regulation competence. Emotion. 2020;doi: 10.1037/emo0000902.
Skymba, H. V., Troop-Gordon, W., Modi, H. H., Davis, M. M., Weldon, A. L., Xia, Y., Heller, W., & Rudolph, K. D. (2020). Emotion mindsets and depressive symptoms in adolescence: The role of emotion regulation competence. Emotion (Washington, D.C.), . https://doi.org/10.1037/emo0000902
Skymba, Haley V, et al. "Emotion mindsets and depressive symptoms in adolescence: The role of emotion regulation competence." Emotion (Washington, D.C.) vol. (2020). doi: https://doi.org/10.1037/emo0000902
Skymba HV, Troop-Gordon W, Modi HH, Davis MM, Weldon AL, Xia Y, Heller W, Rudolph KD. Emotion mindsets and depressive symptoms in adolescence: The role of emotion regulation competence. Emotion. 2020 Dec 28; doi: 10.1037/emo0000902. Epub 2020 Dec 28. PMID: 33370145.
Copy Download .nbib Format: NLM
Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan.

European thyroid journal

Danno H, Nishihara E, Kousaka K, Nakamura T, Kasahara T, Kudo T, Ito M, Fukata S, Nishikawa M, Miyauchi A.
PMID: 34950599
Eur Thyroid J. 2021 Nov;10(6):461-467. doi: 10.1159/000510312. Epub 2020 Sep 30.

INTRODUCTION: Marine-Lenhart syndrome (MLS) is now understood to be a combination of Graves' disease and autonomously functioning thyroid nodule(s) (AFTNs). The prevalence of the syndrome and suitable treatments for those living in iodine-sufficient areas are uncertain.OBJECTIVES: We aimed to...

Cite
Danno H, Nishihara E, Kousaka K, et al. Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan. Eur Thyroid J. 2020;10(6):461-467doi: 10.1159/000510312.
Danno, H., Nishihara, E., Kousaka, K., Nakamura, T., Kasahara, T., Kudo, T., Ito, M., Fukata, S., Nishikawa, M., & Miyauchi, A. (2021). Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan. European thyroid journal, 10(6), 461-467. https://doi.org/10.1159/000510312
Danno, Hirosuke, et al. "Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan." European thyroid journal vol. 10,6 (2021): 461-467. doi: https://doi.org/10.1159/000510312
Danno H, Nishihara E, Kousaka K, Nakamura T, Kasahara T, Kudo T, Ito M, Fukata S, Nishikawa M, Miyauchi A. Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan. Eur Thyroid J. 2021 Nov;10(6):461-467. doi: 10.1159/000510312. Epub 2020 Sep 30. PMID: 34950599; PMCID: PMC8647058.
Copy Download .nbib Format: NLM
HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability.

Gastroenterology

Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Yuka M, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H.
PMID: 34687740
Gastroenterology. 2021 Oct 21; doi: 10.1053/j.gastro.2021.10.010. Epub 2021 Oct 21.

BACKGROUND & AIMS: A detailed understanding of antitumor immunity is essential for optimal cancer immune therapy. Although defective mutations in the B2M and HLA-ABC genes, which encode molecules essential for antigen presentation, have been reported in several studies, the...

Cite
Kawazu M, Ueno T, Saeki K, et al. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.010.
Kawazu, M., Ueno, T., Saeki, K., Sax, N., Togashi, Y., Kaneseki, T., Chida, K., Kishigami, F., Sato, K., Kojima, S., Otsuka, M., Kawazoe, A., Nishinakamura, H., Yuka, M., Yamamoto, Y., Yamashita, K., Inoue, S., Tanegashima, T., Matsubara, D., Tane, K., Tanaka, Y., Iinuma, H., Hashiguchi, Y., Hazama, S., Khor, S. S., Tokunaga, K., Tsuboi, M., Niki, T., Eto, M., Shitara, K., Torigoe, T., Ishihara, S., Aburatani, H., Haeno, H., Nishikawa, H., & Mano, H. (2021). HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.010
Kawazu, Masahito, et al. "HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.010
Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Yuka M, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology. 2021 Oct 21; doi: 10.1053/j.gastro.2021.10.010. Epub 2021 Oct 21. PMID: 34687740.
Copy Download .nbib Format: NLM
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.

Cancer research

Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A.
PMID: 34333454
Cancer Res. 2021 Sep 15;81(18):4861-4873. doi: 10.1158/0008-5472.CAN-21-0985. Epub 2021 Jul 31.

Isocitrate dehydrogenase-mutant low-grade gliomas (IDHmut-LGG) grow slowly but frequently undergo malignant transformation, which eventually leads to premature death. Chemotherapy and radiotherapy treatments prolong survival, but can also induce genetic (or epigenetic) alterations involved in transformation. Here, we developed a...

Cite
Aoki K, Suzuki H, Yamamoto T, et al. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Res. 2021;81(18):4861-4873doi: 10.1158/0008-5472.CAN-21-0985.
Aoki, K., Suzuki, H., Yamamoto, T., Yamamoto, K. N., Maeda, S., Okuno, Y., Ranjit, M., Motomura, K., Ohka, F., Tanahashi, K., Hirano, M., Nishikawa, T., Shimizu, H., Kitano, Y., Yamaguchi, J., Yamazaki, S., Nakamura, H., Takahashi, M., Narita, Y., Nakada, M., Deguchi, S., Mizoguchi, M., Momii, Y., Muragaki, Y., Abe, T., Akimoto, J., Wakabayashi, T., Saito, R., Ogawa, S., Haeno, H., & Natsume, A. (2021). Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer research, 81(18), 4861-4873. https://doi.org/10.1158/0008-5472.CAN-21-0985
Aoki, Kosuke, et al. "Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas." Cancer research vol. 81,18 (2021): 4861-4873. doi: https://doi.org/10.1158/0008-5472.CAN-21-0985
Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Res. 2021 Sep 15;81(18):4861-4873. doi: 10.1158/0008-5472.CAN-21-0985. Epub 2021 Jul 31. PMID: 34333454.
Copy Download .nbib Format: NLM
Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT.

Frontiers in neurology

Kanetaka H, Shimizu S, Inagawa Y, Hirose D, Takenoshita N, Sakurai H, Hanyu H.
PMID: 33329310
Front Neurol. 2020 Nov 19;11:568438. doi: 10.3389/fneur.2020.568438. eCollection 2020.

The cingulate island sign (CIS) on fludeoxyglucose (FDG)-positron emission tomography (PET) is a supporting biomarker of dementia with Lewy bodies (DLB). Its diagnostic accuracy has only been investigated in FDG-PET, however. The present prospective study compared the CIS on...

Cite
Kanetaka H, Shimizu S, Inagawa Y, et al. Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. Front Neurol. 2020;11:568438doi: 10.3389/fneur.2020.568438.
Kanetaka, H., Shimizu, S., Inagawa, Y., Hirose, D., Takenoshita, N., Sakurai, H., & Hanyu, H. (2020). Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. Frontiers in neurology, 11568438. https://doi.org/10.3389/fneur.2020.568438
Kanetaka, Hidekazu, et al. "Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT." Frontiers in neurology vol. 11 (2020): 568438. doi: https://doi.org/10.3389/fneur.2020.568438
Kanetaka H, Shimizu S, Inagawa Y, Hirose D, Takenoshita N, Sakurai H, Hanyu H. Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. Front Neurol. 2020 Nov 19;11:568438. doi: 10.3389/fneur.2020.568438. eCollection 2020. PMID: 33329310; PMCID: PMC7710855.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 261 entries